Cigna Group’s Mixed Performance Amid Market Challenges

With a market cap of $84.3 billion, The Cigna Group (CI) stands as a prominent global health services provider based in Bloomfield, Connecticut. The company serves over 178 million customers across more than 30 countries. It operates mainly through two divisions: Cigna Healthcare, which offers medical, dental, vision, and behavioral health insurance, and Evernorth Health Services, which manages pharmacy benefit solutions via brands like Express Scripts and Accredo.

Stock Performance Overview

Over the past year, Cigna has significantly lagged behind the broader market. Cigna’s stock has decreased by 13.5% in the last 52 weeks, in contrast to the S&P 500 Index’s ($SPX) 12.7% gain during the same period. However, year-to-date (YTD), CI stock has increased by 9.3%, outpacing SPX’s minimal gains in 2025.

Comparison with Sector Peers

Examining Cigna’s performance further, the company has underperformed compared to the SPDR S&P Health Care Services ETF’s (XHS) gains of 8.2% over the past year but managed to exceed its 8.8% growth in 2025.

Impact of Regulatory Actions

On May 12, Cigna Group’s stock dropped over 5%, reflecting broader market conditions. This decline was influenced by an executive order from President Trump criticizing pharmacy benefit managers (PBMs), a critical component of Cigna’s Evernorth division. The overall negative sentiment towards health insurers added to the pressure on the stock.

Financial Projections and Analyst Ratings

For the current fiscal year ending in December, analysts predict that Cigna will achieve an 8.6% year-over-year increase in non-GAAP earnings, reaching $29.69 per share. Historically, the company has had a mixed earnings track record, exceeding Wall Street estimates in three out of the last four quarters but falling short in one.

Among the 21 analysts monitoring CI stock, the consensus rating is a “Strong Buy.” This rating comprises 15 “Strong Buy,” two “Moderate Buy,” and four “Hold” recommendations.

This consensus is slightly more optimistic than a month ago when 16 analysts issued a “Strong Buy” rating.

On May 12, Truist Securities analyst David Macdonald increased Cigna Group’s price target from $385 to $405 while maintaining a “Buy” rating. Cigna’s average price target of $377.80 suggests a 25.1% upside from current levels, while its highest target of $407 indicates a potential upside of 34.8%.

On the date of publication, Kritika Sarmah did not hold (either directly or indirectly) positions in any of the securities mentioned in this article. The information provided is solely for informational purposes. For further details, please see the Barchart Disclosure Policy here.

The views and opinions expressed in this article are those of the author and do not necessarily reflect those of Nasdaq, Inc.